Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houma, LA
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houma, LA
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lansing, MI
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saginaw, MI
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saginaw, MI
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wyoming, MI
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wyoming, MI
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ypsilanti, MI
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tupelo, MS
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tupelo, MS
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ridgewood, NJ
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gastonia, NC
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gastonia, NC
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
High Point, NC
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Doylestown, PA
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Doylestown, PA
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Langhorne, PA
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Langhorne, PA
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Providence, RI
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rock Hill, SC
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kingsport, TN
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
McKinney, TX
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
McKinney, TX
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tyler, TX
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Waco, TX
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Waco, TX
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Camp Hill, PA
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Camp Hill, PA
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
mi
from
Montreal,
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
mi
from
Montreal,
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pensacola, FL
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saginaw, MI
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saginaw, MI
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rapid City, SD
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
mi
from
Ceske Budejovice,
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
mi
from
Ceske Budejovice,
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Cloud, MN
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Athens, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Athens, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fairhope, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fairhope, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Huntsville, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Anchorage, AK
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Chandler, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Chandler, AZ
Click here to add this to my saved trials